Is Narayana Hrudaya overvalued or undervalued?

As of 27 June 2025, the valuation grade for Narayana Hrudaya has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 58.26, an EV to EBITDA ratio of 36.94, and a PEG ratio of 48.77. These ratios suggest that the stock is trading at a premium compared to its earnings and growth potential. When comparing Narayana Hrudaya to its peers, Max Healthcare has a higher PE ratio of 109.63, while Apollo Hospitals, deemed attractive, has a PE ratio of 72.65. This highlights that Narayana Hrudaya, despite being classified as very expensive, is still more reasonably valued than some competitors. The company's recent stock performance has significantly outpaced the Sensex, with a year-to-date return of 78.86% compared to the Sensex's 7.58%, further emphasizing the disconnect between its high valuation and market fundamentals.